Sorrento gets HCV IP from Ben-Gurion University
Executive Summary
Antibody specialist Sorrento Therapeutics Inc. has received the option to license exclusive global rights from Ben-Gurion University of the Negev to patents and intellectual property surrounding several fully human antibodies that bind to a hepatitis C protease enzyme.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice